The NVIDIA and Eli Lilly co-innovation lab announced January 12, 2026 at the JPM Healthcare Conference is one of the largest disclosed AI collaborations in pharma. It also extends a relationship that has been building as NVIDIA deepens ties across the pharma and life sciences sectors. Framed as up to $1 billion over five years,…
Amgen, Deepcell tap NVIDIA’s AI to drive drug discovery and advance cell morphology research
In 2023, generative AI (GenAI) entered the mainstream, capturing the attention of both the public and a growing number of biotechs. One of the most prominent Big Tech firms driving the trend is NVIDIA, which has forged alliances with biotechs ranging from Genentech, Recursion Pharmaceuticals and Evozyne, among others. The momentum is continuing in early…